The board of directors of Rainmed Medical Limited announced that the Group has recently received approval from the National Medical Products Administration (Guo Jia Yao Pin Jian Du Guan Li Ju) (the "NMPA") for the registration application of coronary artery function measurement system (" caIMR System"), making it the second core product of the Group approved by the NMPA. Index of microvascular resistance ("IMR") is a quantitative method to assess the microvascular function of blood vessels, and is used to identify effective adjunctive treatment to reduce microcirculatory dysfunction and improve future prognosis after percutaneous coronary intervention ("PCI"). IMR can guide the diagnosis and management of patients with coronary artery diseases ("CAD").

Multiple authoritative studies globally have indicated a significant correlation between IMR value and risk for cardiac death or readmission due to heart failure: patients with IMR =25 showed significantly higher risk for cardiac death or read mission due to heart failure than those with IMR <25. In addition, as fractional flow reserve ("FFR") measures the macro-circulation of epicardial arteries which account for 5% of all arteries and IMR measures the microcirculation of pre-arterioles, arterioles and capillaries, which account for 95% of all arteries, therefore, using a combination of IMR and FFR can provide a comprehensive evaluation on coronary circulation status of CAD patients. According to China Insights Industry Consultancy Limited, an independent market research and consultancy firm principally engaged in the provision of market research and consultancy services, up to 70% of patients receiving coronary angiography have microvascular dysfunction, and thus are in need of IMR measurement.

However, it has been impossible to obtain a precise measurement of IMR without invasive procedures thus far, which makes IMR measurement time-consuming and inconvenient for clinical use due to the complexity of the operation.